Antithyroid drugs and birth defects [PDF]
Thyroid Research, 2020 Antithyroid drugs (ATDs) are preferred for the treatment of hyperthyroidism caused by Graves’ disease in pregnant women. The drugs have been a recognized treatment for decades, and a general risk of side effects is known. For the use of ATDs in pregnancy,
Stine Linding Andersen, Stig Andersen
doaj +7 more sources
An Overview on the Proposed Mechanisms of Antithyroid Drugs-Induced Liver Injury [PDF]
Advanced Pharmaceutical Bulletin, 2015 Drug-induced liver injury (DILI) is a major problem for pharmaceutical industry and drug development. Mechanisms of DILI are many and varied.
Reza Heidari +4 more
doaj +3 more sources
Factors affecting drug-induced liver injury: antithyroid drugs as instances [PDF]
Clinical and Molecular Hepatology, 2014 Methimazole and propylthiouracil have been used in the management of hyperthyroidism for more than half a century. However, hepatotoxicity is one of the most deleterious side effects associated with these medications.
Reza Heidari +3 more
doaj +2 more sources
Predicting remission of Graves' disease following treatment with antithyroid drugs
Клинический разбор в общей медицине, 2023 Graves' disease (GD) is among the most prevalent organ-specific diseases and is one of the most common causes of hyperthyroidism in regions with normal iodine supply.
Natalya V. Drogashevskaya +5 more
doaj +2 more sources
Iran J Pharm Res, 2019 The thionamide drugs, i.e. carbimazole and its metabolite methimazole (MMI), and propylthiouracil (PTU) have extensively been used in the management of various forms of hyperthyroidism over the past eight decades. This review aims to summarize different aspects of these outstanding medications.
Abdi H, Amouzegar A, Azizi F.
europepmc +3 more sources
Thyroidectomy versus antithyroid drugs in Graves’ disease: a meta-analysis of randomized controlled trials [PDF]
BMC SurgeryObjective This meta-analysis was developed to compare the clinical outcomes associated with thyroidectomy and antithyroid drug treatment in Graves’ disease patients, with a focus on outcomes including ophthalmopathy onset or progress, the hyperthyroid ...
XiaoGang Zheng +4 more
doaj +2 more sources
Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years [PDF]
Frontiers in Endocrinology, 2023 ObjectiveThe authors aimed to investigate the clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years.MethodsThe data of patients with antithyroid drug-induced aplastic anemia were retrieved from PubMed and ...
Ying Cheng +7 more
doaj +2 more sources
The effect of gender on response to antithyroid drugs and risk of relapse after discontinuation of the antithyroid drugs in patients with Graves’ hyperthyroidism: a multicentre study [PDF]
Endokrynologia Polska, 2020 INTRODUCTION: The outcome of medical treatment in patients with Graves’ disease (GD) is generally difficult to predict. In this study, we examined the hypothesis that gender may affect the outcome of treatment with antithyroid drugs (ATDs).
Sayid Shafi Zuhur +10 more
doaj +2 more sources
Therapeutic efficacy of glucocorticoids, ATP, and antithyroid drugs in acute thyrotoxic myopathy: evaluation using the acute thyrotoxic myopathy symptom score [PDF]
Frontiers in EndocrinologyBackgroundAcute thyrotoxic myopathy (ATM) is a relatively rare and severe complication of hyperthyroidism, mainly reported in individual cases and lacking standardized treatment protocols.ObjectiveThis study evaluated the efficacy of glucocorticoids (GCs)
Qiaoli Li +19 more
doaj +2 more sources
A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment [PDF]
Clinical Case Reports, 2018 Key Clinical Message Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3‐6 months after starting treatment.
Hyunsam Kim, Jeongmin Lee, Jeonghoon Ha
doaj +2 more sources